Our unique team of experts brings together experience, passion and expertise from bench to bedside.



Jonathan Lane

General Manager

With a background in molecular biology, Jonathan has worked in biotechnology for over 20 years. After a short but diverse research career, he moved into patent management and business development/licensing roles before co-founding NanoGenics.


Dr Simon Newman

Chief Scientific Officer

As Chief Scientific Officer of NanoGenics, Simon is responsible for the ongoing development of the in-house product pipeline and the continued development of the LipTide platform. Simon has led oncology drug discovery projects and new company spinouts at Imperial College London for ten years. He has published over 60 peer-reviewed papers, which have been cited over 2000 times. Simon has worked with Ipsen, Sterix, and Oxandia Ltd and was Director of Research for Target Ovarian Cancer.


Paul Murray

Executive Chairman

Paul is a chartered accountant with nearly 30 years of experience in the private equity market, having been a director of 3i PLC and a partner in Deutsche Bank’s private equity business. Paul now runs his own private equity fund.

Scientific Advisory Board

Dr (Prof) Alistair Strachan (Chair)


Alistair formerly served as Head of Operations Global Biotherapeutics Technologies at Pfizer, VP of Licensing & Business Development EMEA at Wyeth and Head of Operations, Neurology and GI Centre of Excellence for Drug Discovery at GSK. He was made an honorary professor by the University of Aberdeen in 2012.

Dr (Prof) David Harrison
Dr Aris Tagalakis
Prof Alexander Mullen
Prof Gordon Jayson
Dr Ian Waddell
Dr Frank Fildes
Dr Simon Newman